Metabolic syndrome and atypical antipsychotics: A selective literature review

German Journal of Psychiatry

Volumn 11, Issue 3, 2008, Pages 111-122

  Kannabiran, Muthukumar ^a   Singh, Vinod ^b  

^a GUY S HOSPITAL   (United Kingdom)

^b BIRMINGHAM AND SOLIHULL MENTAL HEALTH NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

Atypical antipsychotic; Metabolic syndrome; Physical health; Severe mental illness

Indexed keywords

ACETYLSALICYLIC ACID; AMANTADINE; ARIPIPRAZOLE; ATOMOXETINE; ATYPICAL ANTIPSYCHOTIC AGENT; CHLORPROMAZINE; CHOLESTEROL; CIMETIDINE; CLOZAPINE; FLUOXETINE; GLUCOSE; HALOPERIDOL; METFORMIN; MOLINDONE; NEUROLEPTIC AGENT; NIZATIDINE; OLANZAPINE; PHENOTHIAZINE; PIMOZIDE; PLACEBO; QUETIAPINE; REBOXETINE; RISPERIDONE; SERTINDOLE; SIBUTRAMINE; TETRAHYDROLIPSTATIN; TOPIRAMATE; ZIPRASIDONE;

BLOOD EXAMINATION; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; COGNITIVE THERAPY; COMORBIDITY; DIABETES MELLITUS; DIABETIC KETOACIDOSIS; DRUG WITHDRAWAL; DYSLIPIDEMIA; EXTRAPYRAMIDAL SYMPTOM; GLUCOSE BLOOD LEVEL; GLUCOSE HOMEOSTASIS; GLUCOSE METABOLISM; GLUCOSE TOLERANCE; HUMAN; HYPERCHOLESTEROLEMIA; HYPERGLYCEMIA; HYPERLIPIDEMIA; HYPERTENSION; HYPERTRIGLYCERIDEMIA; INSULIN RESISTANCE; ISCHEMIC HEART DISEASE; LIFESTYLE MODIFICATION; LOW DRUG DOSE; MENTAL DISEASE; METABOLIC DISORDER; METABOLIC SYNDROME X; NONHUMAN; OBESITY; ORAL GLUCOSE TOLERANCE TEST; PHYSICAL EXAMINATION; PREVALENCE; REVIEW; SCHIZOPHRENIA; SIDE EFFECT; TRIACYLGLYCEROL BLOOD LEVEL; WEIGHT GAIN; WEIGHT REDUCTION;

EID: 56849102843     PISSN: None     EISSN: 14331055     Source Type: Journal    
DOI: None     Document Type: Review

References (76)

1. Alberti KG, Zimmet P & Shaw J (2005) The metabolic syndrome - a new worldwide definition. The Lancet 366:1059-1062
2. Alexander CM, Landsman PB, Teutsch SM & Haffner SM (2003) NCEP-defined metabolic syndrome, diabetes, and prevalence of coronary heart disease among NHANES III participants age 50 years and older. Diabetes 52:1210-1214
3. Alvarez-Jimenez M, Hetrick SE, Gonzalez-Blanch C, et al. (2008) Non-pharmacologic management of antipsychotic-induced weight gain: systematic review and meta-analysis of randomised controlled trials British J Psychiatry 193:101-107
4. Alison & Casey 2001 Kraepelin, E. Dementia Praecox and Paraphrenia Edinburgh, Scotland: E & S Livingstone; 1919.
5. Allison DB, Mentore JL, Heo M, et al. (1999) Antipsychotic-induced weight gain: A comprehensive research synthesis. Am J Psychiatry 156:1686-1696.
6. Almeras N, Depres J-P, Villeneuve J, et al. (2004) Development of an atherogenic metabolic risk factor profile associated with the use of atypical antipsychotics. J Clin Psychiatry 2004 65:557-564
7. Ascher-Svanum H, Stensland MD, Kinon BJ, et al. (2005) Weight gain as a prognostic indicator of therapeutic improvement during acute treatment of shcizophrenia with placebo or active antipsychotic. Jl of Psychopharmacology Supplement 19(6):110-117.
8. Baptista T, Kin NY & Beaulieu S (2002) Novel Antipsychotics and Severe Hyperlipidemia: Comments on the Meyer Paper. Letters to the Editors. J Clin Psychopharmacol, 22(5):536-537
9. Barnett AH, Mackin P, Chaudhry I, et al. (2007) Minimising metabolic and cardiovascular risk factors in schizophrenia: diabetes, obesity and dyslipidaemia J Psychopharmacology 21(4): 357-373
10. Best L, Yates AP, Reynolds G (2005) Actions of antipsychotic drugs on pancreatic b-cell function: contrasting effects of clozapine and haloperidol. J Psychopharmacology 19(6):597-601.
11. Blaha M & Elasy T (2006) Clinical Use of the Metabolic Syndrome: Why the Confusion? Clin Diab 24(3):125-131
12. Brown S, Inskip H & Barraclough, B (2000) Causes of the excess mortality of schizophrenia. British Jl Psychiatry 177:212-217
13. Bushe C, Haddad P, Peveler R & Pendlebury J (2005) The role of lifestyle interventions and weight management in schizophrenia. J Psychopharmacology, Suppl.19(6):28-35..
14. Cassidy F, Ahearn E, Carroll BJ (1999) Elevated frequency of diabetes mellitus in hospitalized manic-depressive patients. Am J Psychiatry 156:1417-1420
15. Cavazzoni P, Mukopadhyay N, Carlson C (2005) Retrospective analysis of risk factors in patients with treatment-emergent diabetes during clinical trials of antipsychotic medications BJPsychiatry (suppl. 47)185:s94-101
16. Consenus develonment conference on antipsychotic drugs and obesity and diabetes: American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologists, North American Association for the study of obesity (2004) Diabetes Care. 27(2):596-601
17. Cormac I, Ferriter M, Bening R et al. (2005) Physical health and health risk factors in a population of long-stay psychiatric patients. Psychiatric Bulletin 29:18-20
18. Correll CU, Frederickson AM, Kane JM et al. (2006) Metabolic syndrome and the risk of coronary heart disease in 367 patients treated with second-generation antipsychotic drugs. J Clin Psychiatry 67:575-583
19. Davis JM, Chen N & Glick ID (2003) A meta-analysis of the efficacy of second-generation antipsychotics. Arch Gen Psychiatry 60:553-564
20. Dixon L, Weiden P, Delahanty J et al. (2000) Prevalence and correlates of diabetes in national schizophrenia samples. Schizophrenia Bulletin 26(4):903-912
21. Dursun S, Dinan T, Bushe C et al. (2005) Challenges in advancing mental and physical health in patients with serious mental illness. J Psychopharmacology 19(6) Supplement:3-5
22. Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on detection, evaluation and treatment of high blood cholesterol in adults (Adult Treatment Panel III) (2001). JAMA 285:2486-2497
23. Ford ES & Giles WH (2003) A comparison of the prevalence of the metabolic svndrome using two proposed definitions. Diabetes Care 26: 575-581
24. Ford ES, Giles WH & Dietz WH (2002) Prevalence of the metabolic syndrome among US adults: findings from the Third National Health and Nutrition Examination Survey. JAMA 287:356-359
25. Gough S & O'Donovan MC (2005) Clustering of metabolic comorbidity it schizophrenia: a, genetic contribution? J Psychopharmacology 19(6) Supplement:47-55.
26. Greening(2005) Physical health of patients in rehabilitation and recovery: a survey of case note records Psychiatric Bulletin 29:210-212
27. Grundy SM, Cleeman JI, Daniels SR et al. (2005) Diagnosis and Management of the Metabolic Syndrome. AHA/NHLBI Scientific Statement. Circulation 112:0000-0000.
28. Gupta S, Steinmeyer C, Frank B, Madhusoodanan S, Lockwood K, Lentz B & Keller P (2003) Hyperglycemia and Hypertriglyceridemia in Real World Patients on Antipsychotic Therapy. Am J Therapeutics 10:348-355
29. Haddad P (2005) Weight change with atypical antipsychotics in the treatment of schizophrenia. Jl of Psychopharmacology 19(6) (Supplement):16-27
30. Heiskanen T, Niskanen L, Lyytikainen R, Saarinen PI, Hintikka J (2003) Metabolic syndrome in patients with schizophrenia. J Clin Psychiatry 64:575-579
31. Henderson et al. (2005) Glucose Metabolism in Patients With Schizophrenia Treated with Atypical Antipsychotic Agents. Arch Gen Psychiatry 62:19-28
32. Henderson DC, Cagliero E, Gray C et al. (2000) Clozapine, Diabetes Mellitus, Weight Gain and Lipid Abnormalities: A Five-Year Naturalistic Study. American Jl Psychiatry 157:975-981.
33. Holt RG, Peveler RC & Byrne CD (2004) Schizophrenia, the metabolic syndrome and diabetes. Diab Med 21:515-523
34. IDF (2006) The IDF consensus worldwide definition of the metabolic syndrome. International Diabetes Federation (IDF), 2006. www.idf.org
35. Isomaa B, Almgren P, Tuomi T, Forsen B et al. (2001) Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care 24:683-689
36. Jones PB, Barnes TR, Davies L, et al. (2006) Randomized controlled trial of effect of quality of life of second-vs first generation antipsychotic drugs in schizophrenia. Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1). Arch Gen Psychiatry 63:1079-1087
37. Kwon JS, Choi J-S, Bahk W-M et al. (2006) Weight management program for treatment-emergent weight gain in Olanzapine-treated patients with Schizophrenia or Schizoaffective disorder: a 12 week randomized controlled clinical trial. J Clin Psychiatry 67:547-553
38. Kohen D (2004) Diabetes mellitus and schizophrenia: Historical perspective. BJPsych (suppl.- 47)184: s64-s66
39. Koro et al. (2002) Assessment of independent effect of olanzapine and risperidone on risk of diabetes among patients with schizophrenia: population based nested case-control study. BMJ 325:243-247
40. Koro C, Fedder DI, L'Italien JL et al. (2002) An assessment of the independent effects of olanzapine and risperidone exposure on the risk of hyperlipidemia in schizophrenic patients. Arch Gen Psychiatry 59:1021-1026
41. Lesage AD, Trapani V, Tansella M (1990) Excess mortality by natural causes of Italian schizophrenic patients. Eur Arch Psychiatry Neurol Sci. 239(6):361-5
42. Lieberman JA (2004) Metabolic Changes Associated with Antipsychotic Use. J Clin Psychiatry 6(suppl 2): 8-13
43. Lieberman JA, Tollefson G, Tohen M, et al. (2003) Comparative efficacy and safety of atypical and conventional antipsychotic drug in first -episode psychosis: A randomized double-blind trial of olanzapine versus haloperidol. Am J Psychiatry 160:1396-1404
44. Lindenmayer J-P & Patel, R. (1999) Olanzapine-induced Ketoacidosis with Diabetes Mellitus. Am J of Psychiatry 156:1471
45. Lindenmayer J-P, Czobor P, Volavka J, et al. (2003) Changes in glucose and cholesterol levels in patients with schizophrenia treated with typical or atypical antipsychotics. American Jl Psychiatry 160:290-296
46. Lund BC, Perry PJ, Brooks JM and Arndt S (2001) Clozapine use in patients with schizophrenia and the risk of diabetes, hyperlipidemia and hypertension. Arch Gen Psych 58:1172-1176
47. Mackin P, Watkinson HM & Young AH (2005) Prevalence of obesity, glucose homeostasis disorders and metabolic syndrome in psychiatric patients taking typical or atypical antipsychotic drugs: a cross-sectional study. Diabetologia 48:212-221.
48. Mackin P, Bishop , Watkinson H et al. (2007) Metabolic disease and cardiovascular risk in people treated with antipsychotics in the community. BJPsych 191:23-29
49. McCreadie R (2003) Diet, smoking and cardiovascular risk in people with schizophrenia. B J Psychiatry 183: 534-539
50. McEvoy JP, Lieberman JA, Stroup TS, et al. (2006) Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone, in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment. Am J Psychiatry 163:600-610
51. McQuade RD, Stock E, Marcus R, et al. (2004) A comparison of weight change during treatment with olanzapine or aripiprazole: results from a randomized, double-blind study. J Clin Psychiatry 65 (suppl 18):47-56
52. Melkersson KI, Dahl ML & Hulting AL (2004) Guidelines for prevention and treatment of adverse effects of antipsychotic drugs on glucose-insulin homeostasis and lipid metabolism. Psychopharmacology 175:1-6.
53. Menzies R, Dyslipidaemia and Psychiatric Patients (2004) Can J Psychiatry 49(12):864
54. Meyer J, Koro C & L'Italien GJ (2005) The Metabolic syndrome and schizophrenia: A review. Int Rev Psychiatry 17(3):173-180
55. Meyer J 2005) Letters to the Editors: Reply to comments made by Baptista et al. J Clin Psychopharm, vol 22(5):538
56. Meyer JM (2001) Novel antipsychotics and severe hyperlipidemia. J Clin Psychopharmacol 21:369-374
57. Newcomer JW, Dan WH, Fucetola R et al. (2002) Abnormalities in glucose regulation during antipsychotic treatment of schizophrenia. Arch Gen Psychiatry 59:337-345
58. Osborn DPJ, Nazareth I & King MB (2006) Risk for coronary heart disease in people with severe mental illness - Cross sectional comparative study in primary care. B J Psych 188:271-277
59. Phelan, Stradins & Morrison(2001) Physical health of people with severe mental illness. BMJ 322:443-4
60. Poyurovsky M, Isaacs I., Fuchs C, et al. (2003) Attenuation of olanzapine-induced weight gain with reboxetine in patients with schizophrenia: A double-blind, placebo-controlled study. Am J Psychiatry 160:297-302
61. Reaven GM (1988) Role of insulin resistance in human disease. Diabetes 37:1595-1607
62. Remington 2006. Ed: Schizophrenia, antipsychotics, and the metabolic syndrome: Is there a silver lining? American Jl Psychiatry 163:7
63. Ryan et al. (2003) Impaired fasting glucose tolerance in first-episode, drug-naïve patients with schizophrenia. Am J Psychiatry 160: 284-289
64. Saari K, Koponen,H, Laitinen J, Jokelainen J, Lauren L, Isohanni M & Lindeman S (2004) Hyperlipidemia in Persons Using Antipsychotic Medication: A General Population-Based Birth Cohort Study. J Clin Psychiatry 65:547-550
65. Sacks F (2004) Metabolic Syndrome: Epidemiology and Consequences. J Clin Psychiatry 65(suppl 18):3-12
66. Sernyak MJ, Leslie DL, Alarcon RD, Losonczy MF, Rosenheck R (2002) Association of diabetes mellitus with use of atypical neuroleptics in the treatment of schizophrenia. Am J Psychiatry 159(4):561-6
67. Sheitman B B,Bird Paula M, Binz Whitney, Akinli, Leyla & Sanches, Clare (1999) Olanzapine-Induced Elevation of Plasma Triglyceride Levels. Am J Psychiatry 156: 1471-1472
68. Sramek JJ, Cutler NR & Shiovitz T (2003) The Effect of Antipsychotics on Plasma Lipids. J Clin Psychopharm, 23(6):679. Letter to Editor
69. Tarrant CJ (2006) Blood glucose testing for adults prescribed atypical antipsychotics in primary and secondary care. Psychiatric Bulletin (2006) 30:286-288.
70. Tarricone I., Casoria M, Gozzi BF, Grieco D, Menchetti M, Serretti A, Ujkaj M, Pastorelli R & Berardi,D (2006) Metabolic risk factor profile associated with use of second generation antipsychotics: a cross sectional study in a community mental health centre. BMC Psychiatry 6:11-18
71. Toalson P, Ahmed S, Hardy T & Kabinoff G (2004) The Metabolic Syndrome in Patients with Severe Mental Illnesses. J Clin Psychiatry 6:152-158
72. Tovey E, Rampes H. & Livingstone C (2005) Clozapine-induced type-2 diabetes mellitus: possible mechanisms and implications for clinical practice. J Psychopharmacology 19(2):207-210
73. Werneke U, Taylor D & Sanders TAB (2002) Options for pharmacological management of obesity in patients treated with atypical antipsychotics. Int Clin Psychopharmacology 17:145-160.
74. Werneke U, Taylor D, Sanders T.AB & Wessely S (2003) Behavioural management of antipsychotic-induced weight gain: a review. Acta Psychiatr Scand 108:252-259
75. Zhang Z-J, Yao Z-J, Liu W et al. (2004) Effects of antipsychotics on fat deposition and changes in leptin and insulin levels. B J Psychiatry 184:58-62
76. Zipursky RB, Gu H, Green AI et al. (2005) Course and predictors of weight gain in people with first-episode psychosis treated with olanzapine or haloperidol. Br J Psychiatry 187:537-543